Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 8
Submit an article Journal homepage
782
Views
3
CrossRef citations to date
0
Altmetric
Commentaries

Chronic myelomonocytic leukemia: molecularly contaminated, but not defined

Mrinal M. PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
&
Ayalew TefferiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
Pages 1751-1752 | Received 04 Mar 2016, Accepted 14 Mar 2016, Published online: 11 Apr 2016

References

  • Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: focus on clinical practice. Mayo Clinic Proc. 2016;91:259–272.
  • Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014; 28:2206–2212.
  • Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385
  • Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–2436.
  • Patnaik MM, Wassie EA, Lasho TL, et al. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015; 90:411–416.
  • Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2002;43:2083–2092.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016. [Epub ahead of print]. DOI: 10.1002/ajh.24333.
  • Elbaek MSA, Hasselbalch H. Chronic inflammation and autoimmunity as risk factors for development of chronic myelomonocytic leukemia?. Leuk Lymphoma. 2016;57:1793–1799. DOI: 10.3109/10428194.2016.1143938.
  • Peker D, Padron E, Bennett JM, et al. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015;133:249–256.
  • Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411.
  • Jo T, Horio K, Migita K. Sweet's syndrome in patients with MDS and MEFV mutations. N Eng J Med. 2015;372:686–688.
  • Perez Botero J, Oliveira JL, Chen D, et al. ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J. 2015;5:e315.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.